Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that management will host a conference call to discuss its third quarter 2021 financial results and provide a business update on Tuesday, November 9, 2021 at 8:30 a.m. ET.
November 2, 2021
· 2 min read